Efficacy of different doses of oliceridine for Patient-Controlled Intravenous Analgesia in patients undergoing Total Laparoscopic Hysterectomy. [PDF]
Deng J +6 more
europepmc +1 more source
Oliceridine versus Hydromorphone for Postoperative Analgesia: Interpreting the PONV Signal and the Limitations of Resting Pain as a Primary Endpoint [Response to Letter]. [PDF]
Jiang Q +6 more
europepmc +1 more source
Oliceridine Versus Hydromorphone for Postoperative Analgesia: Interpreting the PONV Signal and the Limitations of Resting Pain as a Primary Endpoint [Letter]. [PDF]
Li R, Zhao S.
europepmc +1 more source
Oliceridine versus Sufentanil for Postoperative Intravenous Analgesia in Patients Undergoing Abdominal Surgery in the AICU: A Double-Blind Non-Inferiority Trial. [PDF]
Li W +7 more
europepmc +1 more source
Background: G protein-biased mu-opioid receptor (MOR) agonists such as oliceridine and tegileridine were developed to reduce opioid-related side effects while keeping analgesic efficacy.
Qingjun Zeng +5 more
core +2 more sources
Effects of oliceridine-based patient-controlled intravenous administration on postoperative pain and hemodynamic stability in elderly patients undergoing laparoscopic surgery for colorectal cancer. [PDF]
Ding L, Ren X, Pang S, Yang T, Xie S.
europepmc +1 more source
The Effect of Oliceridine versus Sufentanil on the Quality of Postoperative Recovery in Patients Undergoing Laparoscopic Cholecystectomy [Letter]. [PDF]
Shi P, Wu M.
europepmc +1 more source
Comparison of Oliceridine and Hydromorphone for Postoperative Analgesia in Adults Undergoing Lower Limb Fracture Surgery: A Randomized Controlled Non-Inferiority Trial. [PDF]
Jiang Q +6 more
europepmc +1 more source
Oliceridine versus Sufentanil on Postoperative Nausea and Vomiting in Women Undergoing Gynecological Laparoscopic Surgery: A Randomized Double‑Blind Controlled Trial. [PDF]
Liu F +11 more
europepmc +1 more source
Interpreting Respiratory Safety in an Oliceridine Gastroscopy Trial [Letter]. [PDF]
Liu A.
europepmc +1 more source

